Sofie Biosciences is a diagnostics company focused on developing technologies for PET in vivo molecular imaging.In May 2017, Sofie Biosciences entered into a definitive agreement under which it would buy Zevacor Pharma and its high-performance manufacturing and distribution network of PET imaging diagnostics and radio-therapeutics. The transaction was subject to closing conditions, which were expected to finalize in the next 60 to 90 days. In September 2017, the acquisition was completed to form SOFIE.In June 2016, the company completed a $3.7 million financing, representing an oversubscription of nearly $1 million